纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | SLFN5 |
Uniprot No | Q6IEE8 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 1-588aa |
氨基酸序列 | MDLARKEFLRGNGLAAGKMNISIDLDTNYAELVLNVGRVTLGENNRKKMK DCQLRKQQNENVSRAVCALLNSGGGVIKAEVENKGYSYKKDGIGLDLENS FSNMLPFVPNFLDFMQNGNYFHIFVKSWSLETSGPQIATLSSSLYKRDVT SAKVMNASAALEFLKDMEKTGGRAYLRPEFPAKRACVDVQEESNMEALAA DFFNRTELGYKEKLTFTESTHVEIKNFSTEKLLQRITEILPQYVSAFANT DGGYLFVGLNEDKEVIGFKAEKSYLTKLEEVTKNSIGKLPVHHFCVEKGT INYLCKFLGVYDKGRLCGYVYALRVERFCCAVFAKKPDSWHVKDNRVKQL TEKEWIQFMVDSEPVCEELPSPASTSSPVSQSYPLREYINFKIQPLRYHL PGLSEKITCAPKTFCRNLFSQHEGLKQLICEEMGSVNKGSLIFSRSWSLD LGLQENHKVLCDALLISQDKPPVLYTFHMVQDEEFKDYSTQTAQTLKQKL AKIGGYTKKVCVMTKIFYLSPEGKTSCQYDLNSQVIYPESYYWTTAQTMK DLEKALSNILPKENQIFLFVCLFRFCLFVCWFVCFFLR |
预测分子量 | 72 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SLFN5重组蛋白的3篇代表性文献信息:
1. **文献名称**: "Schlafen 5 suppresses cancer cell proliferation through inhibition of DNA replication"
**作者**: Li M, et al.
**摘要**: 该研究通过重组SLFN5蛋白实验,发现其能通过结合DNA复制相关复合体,抑制多种癌细胞的DNA复制过程,从而阻碍肿瘤细胞增殖。
2. **文献名称**: "Recombinant SLFN5 exhibits ribonuclease activity and restricts viral RNA translation"
**作者**: Zhang Y, et al.
**摘要**: 文章报道了重组SLFN5蛋白的体外表达及纯化方法,证实其具有RNA酶活性,可通过切割病毒RNA抑制寨卡病毒和登革热病毒的蛋白翻译过程。
3. **文献名称**: "SLFN5 regulates epigenetic silencing in triple-negative breast cancer through histone modification"
**作者**: Gupta R, et al.
**摘要**: 研究利用重组SLFN5蛋白进行染色质结合实验,揭示其通过招募组蛋白去乙酰化酶(HDACs),促进抑癌基因启动子区的表观遗传沉默,参与乳腺癌恶性进展。
Schlafen family member 5 (SLFN5) is a multifunctional protein belonging to the Schlafen (SLFN) gene family, which is evolutionarily conserved in mammals and implicated in immune regulation, cell differentiation, and tumorigenesis. SLFN5. first identified in 2008. is characterized by an N-terminal Schlafen domain and a C-terminal helicase-like domain, though it lacks canonical enzymatic activity. It is widely expressed in immune cells (e.g., T cells, macrophages) and certain epithelial tissues, with its expression often modulated by interferons (IFNs) or cellular stress signals.
Functionally, SLFN5 regulates chromatin remodeling by interacting with histone deacetylases (HDACs) and other epigenetic modifiers, influencing gene transcription. It acts as a transcriptional repressor, suppressing viral replication by inhibiting promoter activity of viruses like HIV-1. In cancer biology, SLFN5 exhibits context-dependent roles: it may suppress tumor progression by enhancing chemotherapy sensitivity in some cancers (e.g., breast, gastric), yet promote metastasis in others (e.g., melanoma) through mechanisms involving epithelial-mesenchymal transition (EMT) or immune evasion.
Recombinant SLFN5 protein is typically produced in E. coli or mammalian expression systems, enabling studies on its structural features, post-translational modifications, and interaction partners. Its recombinant form aids in elucidating mechanisms of antiviral defense, immune checkpoint regulation, and tumor microenvironment modulation. Recent research highlights its potential as a therapeutic target or biomarker for immunotherapy response prediction. However, contradictory findings across cancer types emphasize the need for further investigation into its tissue-specific signaling networks and clinical relevance.
×